Key Highlights

  • Shares rose 1.27% to USD 161.45 on relative Volume of 2.15.
  • Third-quarter net loss was USD 407.5 million, or USD 1.90 per share.
  • Product revenue, net was USD 197.6 million, with none a year earlier.
  • 2026 GAAP operating expenses are guided to USD 2.1 billion to USD 2.2 billion.

Revolution Medicines (NASDAQ:RVMD) shares traded at USD 161.45 on November 20, 2026, up 1.27%, with a relative volume at time of 2.15. The company has given no reason for the heavy trading. It filed its Quarterly Report on November 4 and held its Earnings Call on November 5, so its results predate the session.

Revolution Medicines is a Delaware corporation based in Redwood City, California, founded in October 2014. It is a global, commercial-stage oncology company that discovers, develops and delivers medicines for RAS-addicted cancers. Its only approved product is RASONQUE (daraxonrasib), a multi-selective inhibitor of RAS(ON) variants. FDA approval came in August 2026, and U.S. sales Revenue began that month.

The Third Quarter

Product revenue, net was USD 197.6 million, with no revenue a year earlier. Cost of sales was USD 0.33 million. Research and Development expense was USD 417.1 million versus USD 262.5 million, and selling, general and administrative expense was USD 153.3 million versus USD 52.8 million.

Total costs and expenses were USD 570.7 million versus USD 315.3 million. Loss from operations was USD 373.1 million versus USD 315.3 million. Non-operating expense, net was USD 36.7 million versus non-operating income of USD 10.1 million. The net loss was USD 407.5 million, or USD 1.90 per share, versus USD 305.2 million, or USD 1.61.

Nine Months

Product revenue, net was USD 197.6 million. Research and development expense was USD 1.16 billion versus USD 692.4 million, and selling, general and administrative expense was USD 364.8 million versus USD 128.4 million. Loss from operations was USD 1.32 billion versus USD 820.7 million.

Non-operating expense, net was USD 184.5 million versus income of USD 54.3 million. The net loss was USD 1.51 billion, or USD 7.24 per share, versus USD 766.4 million, or USD 4.06.

Balance Sheet, Liquidity and Cash Flow

Cash was USD 615.9 million versus USD 383.7 million at December 31, 2025, and marketable securities were USD 3.04 billion versus USD 1.64 billion. Total Assets were USD 4.30 billion versus USD 2.35 billion, liabilities were USD 1.90 billion versus USD 723.2 million and Equity was USD 2.40 billion versus USD 1.63 billion.

The company has posted net operating losses every year since inception, with an accumulated Deficit of USD 4.4 billion. Operating Activities used USD 1.16 billion over nine months versus USD 623.5 million, while financing provided USD 2.81 billion versus USD 255.9 million.

Regulatory Update and Outlook

In October, the European Medicines Agency committee for human medicines adopted a positive opinion recommending Marketing authorization for daraxonrasib in the European Union. It covers adults with metastatic pancreatic adenocarcinoma who have had at least one prior systemic therapy. The European Commission will review the opinion and decide on authorization.

On the November 5 call, management reiterated 2026 GAAP Operating Expense guidance of USD 2.1 billion to USD 2.2 billion, including expected noncash stock-based compensation of USD 270 million to USD 290 million. It expects to complete global enrollment in the RASolute 303 study in the first half of 2027 and to share initial RMC-7 monotherapy clinical data in 2027.

What to Watch Next for Revolution Medicines

The company has given no reason for the November 20 trading, and its results and regulatory news came earlier. The reported record shows first product revenue, a wider loss and a much larger cash and securities base. The European Commission decision is the next dated regulatory step.